REGENERON PHARMACEUTICALS INC. - COMMON STOCK

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD

31 May 2024 00:05:00 By Nasdaq GlobeNewswire

Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

31 May 2024 00:00:00 By Nasdaq GlobeNewswire

Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO

23 May 2024 16:03:17 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine

20 May 2024 13:15:00 By Nasdaq GlobeNewswire

More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024

17 May 2024 12:45:49 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)

13 May 2024 00:00:00 By Nasdaq GlobeNewswire

Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks

08 May 2024 05:00:57 By Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentations

06 May 2024 15:05:00 By Nasdaq GlobeNewswire

Regeneron Reports First Quarter 2024 Financial and Operating Results

02 May 2024 05:30:00 By Nasdaq GlobeNewswire

EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases

29 Apr 2024 06:00:18 By Nasdaq GlobeNewswire

Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases

25 Apr 2024 06:00:00 By Nasdaq GlobeNewswire

Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO

24 Apr 2024 09:05:18 By Nasdaq GlobeNewswire

Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)

22 Apr 2024 16:54:01 By Nasdaq GlobeNewswire

Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma

07 Apr 2024 15:00:12 By Nasdaq GlobeNewswire

Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024

01 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Regeneron Provides Update on Biologics License Application for Odronextamab

25 Mar 2024 06:00:02 By Nasdaq GlobeNewswire

High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization

12 Mar 2024 20:30:22 By Nasdaq GlobeNewswire

Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

11 Mar 2024 06:00:23 By Nasdaq GlobeNewswire

EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet

08 Mar 2024 06:00:26 By Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

28 Feb 2024 08:48:56 By NetDania Notify